Lynne Knowles, MD
Gynecologic Oncology · Austin, TXNPI 1568561397
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (48.7%), food and beverage and education — rather than concentrated in one kind of arrangement. 9 manufacturers reported payments, led by AstraZeneca at 58.3% of the total. Reporting peaked in 2023 at $2,148 and has fallen 88.8% since, to $240 in 2025.
Across 59 payments — averaging $59.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Myriad Genetic Laboratories, Inc.$543
- Intuitive Surgical$251
- Merck$196
- Davol Inc.$190
- Seagen Inc.$155
- plus $132 from 3 others
Across 542 payments — averaging $2480.30 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$648K
- Pfizer$551K
- Alkermes, Inc.$132K
- AstraZeneca$10K
- Organon$3K
What the payments were for
- Consulting fees$1,71349%
- Food & beverage$1,70448%
- Education$1013%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 16 | $2,051 |
| Myriad Genetic Laboratories, Inc. | 19 | $543 |
| Intuitive Surgical | 4 | $251 |
| Merck | 8 | $196 |
| Davol Inc. | 2 | $190 |
| Seagen Inc. | 5 | $155 |
| Lilly USA, LLC | 3 | $106 |
| Eisai Inc. | 1 | $25 |
| Clovis Oncology, Inc. | 1 | $1 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYNPARZA$1,713
- myRisk$114
- myChoice CDx$102
- BD MAX$102
How this compares
$3,518 in reported general payments places this provider in the 55th percentile of 135 gynecologic oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LynparzaOlaparib | 29 | $408,934 |
| EliquisApixaban | 11 | $10,130 |
| Letrozole | 65 | $823 |
| Megestrol Acetate | 16 | $728 |
| Gabapentin | 79 | $707 |
| Estradiol | 24 | $690 |
| Dexamethasone | 55 | $558 |
| Ondansetron OdtOndansetron | 29 | $326 |
| Prochlorperazine Maleate | 21 | $245 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 13 | $225 |
| Oxycodone Hcl | 45 | $191 |
| Metronidazole | 16 | $101 |
| Fluoxetine Hcl | 15 | $97 |
| Amlodipine Besylate | 13 | $89 |
| Neomycin Sulfate | 15 | $78 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaLynparza | $2,051 | $408,93429 claims |
| Lilly USA, LLCOlanzapine | $106 | $3721 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 135 gynecologic oncology providers in Texas.
Other gynecologic oncology in Austin
- Helen EshedAustin$35K
- Priyanka KamathAustin$4K
- Robert ColemanHouston$864K
- Reagan StreetFort Worth$280K
- Joseph de la GarzaSan Antonio$234K
- Maurie MarkmanHouston$204K
- Dustin MandersDallas$171K
- Tiffany RedfernFort Worth$165K
- Antonio Santillan-GomezSan Antonio$162K
- Michael FrumovitzHouston$156K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.